Search the Newsreel

Bausch + Lomb (BLCO) Could Be 57% Undervalued As Board Refresh Draws Attention

Form 8K Bausch & Lomb Corp For: 12 August By Investing.com

This article reports on the filing of Form 8K by Bausch & Lomb Corp (BLCO) for August 12. It includes a brief mention of the company's stock performance, noting a 1.31% increase. The content primarily consists of navigational elements, market data tables, and trending …

Bausch + Lomb (NYSE:BLCO) CAO Sells 52,900 Shares

Bausch + Lomb's Chief Accounting Officer, Frederick Munsch, sold 52,900 shares of the company's stock for approximately $887,662, reducing his direct holdings by over 53%. The transaction occurred on Monday, August 10th, and was disclosed in an SEC filing. Despite the insider sale, BLCO …

Bausch & Lomb (BLCO) SVP Frederick Munsch sells 52,900 shares in August trade

Frederick Munsch, SVP, Controller and CAO of Bausch & Lomb Corp (BLCO), sold 52,900 common shares on August 10, 2026, at a weighted average price of $16.78 per share. The sales occurred in multiple trades ranging from $16.73 to $16.85, leaving him with 45,831 …

Is Bausch + Lomb’s Raised 2026 Outlook And Board Refresh Altering The Investment Case For BLCO?

Bausch + Lomb (BLCO) reported Q2 2026 revenue of US$1.39 billion and a reduced net loss of US$14 million, leading to a raised full-year 2026 revenue guidance of US$5.44 billion–US$5.54 billion. Concurrently, the company appointed four new directors to its board, aiming to enhance …

Bausch & Lomb Corp (BLCO) Director Andrew C. von Eschenbach Sells 18,559 Shares

Bausch & Lomb Corp (BLCO) Director Andrew C. von Eschenbach sold 18,559 shares for approximately $306,780, reducing his direct ownership to 63,733 shares. Despite this sale, GuruFocus's valuation model suggests the stock is modestly undervalued, and broader insider activity shows significantly more buying than …

Insider Selling: Bausch + Lomb (NYSE:BLCO) Director Sells $100,458.22 in Stock

Bausch + Lomb (NYSE:BLCO) director Andrew Von Eschenbach sold 6,059 shares of the company's stock for approximately $100,458 at an average price of $16.58, reducing his ownership by 8.68%. Following this transaction, his remaining stake is valued at over $1 million. The company's stock …

Bausch & Lomb (NYSE: BLCO) director sells 18,559 shares after board exit

Bausch & Lomb Corp director Andrew C. Von Eschenbach sold a total of 18,559 common shares in two open-market transactions on August 6 and 7, 2026, after resigning from the board on August 5, 2026. The sales occurred at weighted average prices of $16.50 …

Bausch + Lomb Corporation (BLCO): Growth Potential and Analyst Ratings Point to an 11% Upside

Bausch + Lomb Corporation (BLCO) is showing an 11% upside potential based on analyst ratings, with an average target price of $18.63. Despite reporting a current loss, the company boasts a healthy 9.10% revenue growth and positive free cash flow of $323 million, suggesting …

Bausch + Lomb Updates Board, Reaffirms 2026 Guidance

Bausch + Lomb Corporation announced changes to its board of directors, appointing four new members following a request from majority stakeholder Bausch Health Companies Inc. The company also reaffirmed its full-year 2026 guidance, which includes revenue projections between $5.440 billion and $5.540 billion, and …

Bausch & Lomb Corp (BLCO) EVP awarded 20,973 PSUs after targets met

Bausch & Lomb Corp's EVP of R&D and CMO, Yehia Hashad, was awarded 20,973 Common Shares after performance stock units (PSUs) granted on February 28, 2024, achieved their target performance level (100%) as of August 5, 2026. These shares will vest on February 28, …

Bausch + Lomb (BLCO) Q2 2026 Earnings Call Transcript

Bausch Lomb (BLCO) investor plans sale of 12,500 common shares

A shareholder of Bausch Lomb Corporation (BLCO) plans to sell 12,500 common shares with an aggregate market value of $206,192.77. The shares were acquired through open market purchases in May 2025 and February 2026. As of August 7, 2026, the company has 357,165,246 common …

Bausch & Lomb Corp (BLCO) awards 16,778 performance-based shares to executive

Bausch & Lomb Corp (BLCO) awarded 16,778 performance-based shares to President, GPIC, Andrew J. Stewart. These shares, part of an original grant from February 28, 2024, were earned at the 100% target level on August 5, 2026, and will vest on February 28, 2027, …

Bausch & Lomb (NYSE: BLCO) CLO earns 33,557 performance-based shares

Robert D. Bailey, EVP & Chief Legal Officer of Bausch & Lomb Corp (NYSE: BLCO), was awarded 33,557 common shares from performance stock units that achieved 100% of their target conditions as of August 5, 2026. These shares are scheduled to vest on February …

Stocks in play: Bausch + Lomb Corporation

Bausch + Lomb Corporation announced changes to its Board of Directors, leading to a slight drop in its share price. The shares of T.BLCO are currently trading down $0.20 at $16.54. This brief update highlights recent company news affecting its stock performance.

Bausch + Lomb Corporation (BLCO.TO) Stock Price, News, Quote & History

This article provides comprehensive financial information for Bausch + Lomb Corporation (BLCO.TO), including its stock price, news, quotes, and historical data. It details the company's segments (Vision Care, Pharmaceuticals, and Surgical), recent earnings reports, and analyst ratings, highlighting a recent increase in revenue guidance …

Bausch & Lomb Corp SEC Filing (Aug 6, 2026)

Bausch & Lomb Corp (BLCO) filed a Form 144 on August 6, 2026, indicating a proposed sale of 12,500 shares of common stock with an aggregate market value of $206,192.77. The shares were acquired on April 23, 2023, through restricted stock vesting as compensation. …

Bausch + Lomb Corporation

Bausch + Lomb Corporation announced changes to its Board of Directors on August 6, 2026. Following this news, the company's shares (T.BLCO) were trading down by $0.20 at $16.54. This update was reported by Glenn Wilkins.

Form 8K Bausch & Lomb Corp For: 6 August By Investing.com

Bausch & Lomb Corp filed a Form 8K on August 6, 2026. The article from Investing.com announces this filing but does not provide further details regarding the content of the Form 8K.

Bausch Health requests four new Bausch + Lomb directors with about 87% stake

Bausch Health CEO Thomas J. Appio Joins Bausch + Lomb Board

Bausch Health Companies Inc. announced that its CEO, Thomas J. Appio, has been appointed to the board of directors of its subsidiary, Bausch + Lomb Corporation, effective August 5, 2026. This appointment, along with the addition of three other new directors, was requested by …

HC Wainwright Reduces Earnings Estimates for Bausch + Lomb

H.C. Wainwright raises Bausch & Lomb stock price target to $21

H.C. Wainwright has increased its price target for Bausch & Lomb Corp. (NYSE:BLCO) to $21 from $20, maintaining a Buy rating after the company reported strong second-quarter 2026 financial results. Bausch & Lomb exceeded revenue projections with $1,394 million and saw growth across all …

Bausch + Lomb Introduces New Eyecare Professional Hub

Bausch + Lomb has launched a new Eyecare Professional Hub, centralizing scientific publications, clinical evidence, educational resources, and upcoming events for eyecare professionals. This platform aims to simplify access to critical information, supporting ECPs in their practice and patient care. The hub provides details …

Brokers Offer Predictions for Bausch + Lomb Q1 Earnings

Did Bausch + Lomb’s Stronger Q2 and Higher 2026 Revenue Guidance Just Shift BLCO’s Investment Narrative?

H.C. Wainwright Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Raises Target Price to $21

H.C. Wainwright has reiterated its Buy rating for Bausch + Lomb Corp. (BLCO.US) and increased the price target to $21. This indicates a positive outlook from the analyst firm regarding the company's future stock performance.

Bausch + Lomb Corporation (BLCO) Investor Outlook: Analyzing Its 9.65% Potential Upside

Bausch + Lomb Corporation (BLCO), an eye health leader with a $6.04 billion market cap, shows a 9.65% potential upside despite a negative EPS and ROI. The company's robust revenue growth of 9.10% across its Vision Care, Pharmaceuticals, and Surgical segments, along with a …

RBC Capital Keeps Their Buy Rating on Bausch + Lomb Corporation (BLCO)

RBC Capital analyst Douglas Miehm reiterated a Buy rating on Bausch + Lomb Corporation (BLCO) with a price target of $21.00. This follows a Buy rating from UBS and a Sell rating from Bank of America Securities. The company reported a Q2 revenue of …

RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21

RBC Capital has reiterated its Buy rating for Bausch + Lomb Corp. (BLCO.US) and maintained its target price at $21. This indicates continued confidence in the company's performance and future outlook from the investment bank.

Bausch + Lomb Corporation Revenue Breakdown – NYSE:BLCO

Bausch + Lomb (BLCO) Lifts 2026 Revenue Guidance, Is The Stock Still 57% Undervalued?